Public-private collaboration for multidrug-resistant tuberculosis control in New York City

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 6, 2006, Pages 639-648

  Munsiff, S S ^a   Ahuja, Shama Desai ^a,b   Li, J ^a   Driver, C R ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

Author keywords

Drug therapy; Multidrug resistant; Treatment effectiveness; Treatment outcome; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG CAVITATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW YORK CITY; PRIVATE SECTOR; PUBLIC SECTOR; RETROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 33744924753     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Espinal M A, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculous drugs. N Engl J Med 2001; 344: 1294-1303.
2. Edlin B R, Tokars J I, Grieco M H, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326: 1514-1521.
3. Fischl M A, Reyes R, Cleary T, et al. Nosocomial transmission of multidrug-resistant tuberculosis among HIV infected persons-Florida and New York, 1988-1991. MMWR 1991; 40: 585-591.
4. Hewlett D Jr, Franchini D, Horn D, et al. Outbreak of multidrug-resistant tuberculosis at a hospital-New York City, 1991. MMWR 1993; 42: 427-B4.
5. Pearson M L, Jereb J A, Frieden T R, et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers. Ann Intern Med 1992; 117: 191-196.
6. Valway S E, Greifinger R B, Papania M, et al. Multidrug-resistant tuberculosis in the New York State Prison System, 1990-1991. J Infect Dis 1994; 170: 151-156.
7. Frieden T R, Sherman L F, Maw K L, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276: 1229-1235.
8. Frieden T R, Sterling T, Pablos-Mendez A, Kilburn J O, Cauthen G M, Dooley S W. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-526.
9. Mannheimer S, Sepkowitz K, Stoeckle M Y, Friedman C R, Hafner A, Riley L W. Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multidrug-resistant tuberculosis in New York City. Int J Tuberc Lung Dis 1997; 1: 319-325.
10. Park M M, Davis A L, Schluger N W, Cohen H, Rom W N. Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-324.
11. Salomon N, Perlman D C, Friedman P, Buchstein S, Kreiswirth B N, Mildvan D. Predictors and outcome of multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21: 1245-1252.
12. Turett G S, Telzak E E, Torian L V, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21: 1238-1244.
13. Telzak E E, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907-911.
14. Dorsinville M S. Case management of tuberculosis in New York City. Int J Tuberc Lung Dis 1998; 2 (Suppl 1): S46-S52.
15. Fujiwara P I, Larkin C, Frieden T R. Directly observed therapy in New York City. History, implementation, results, and challenges. Clin Chest Med 1997; 18: 135-148.
16. Gasner M R, Maw K L, Feldman G E, Fujiwara PI, Frieden T R. The use of legal action in New York City to ensure treatment of tuberculosis. N Engl J Med 1999; 340: 359.
17. World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world, Third Global Report. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1999-2002. Geneva, Switzerland: WHO, 2004.
18. Hawkins J E, Wallace R J Jr, Brown B A. Antibacterial susceptibility tests: mycobacteria. In: Balous A, Hausler W J, Herrmann K L, Isenberg H D, Shadomy H J, eds. Manual of Clinical Microbiology. 5th ed. Washington DC: American Society for Microbiology, 1991: pp 1138-1152.
19. Kent P T, Kubica G P. Public Health Mycobacteriology: a guide for the Level III laboratory. Atlanta, GA: Department of Health and Human Services, 1985.
20. Yew W W, Chan C K, Chau C H, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 2000; 117: 744-751.
21. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
22. Kim H J, Hong Y P, Kim S J, Lew W J, Lee E G. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis 2001; 5: 1129-1136.
23. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
24. Park S K, Kim C T, Song S D. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998; 2: 877-884.
25. Tahaoglu K, Törün T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
26. Pablos-Mendez A, Sterling T R, Frieden T R. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276: 1223-1228.
27. Albert H, Trollip A P, Mole R J, Hatch SJB, Blumberg L. Rapid indication of multidrug-resistant tuberculosis from liquid cultures using FASTPlaqueTB-RIF™, a manual phage-based test. Int J Tuberc Lung Dis 2002; 6: 523-528.
28. Watterson S A, Wilson S M, Yates M D, Drobniewski F A. Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol 1998; 36: 1969-1973.
29. Bureau of Tuberculosis Control. Information Summary, 1997. New York, NY: New York City Department of Health, 1998.
30. Iseman M D. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-791.
31. New York City Bureau of Tuberculosis Control. Clinical Policies and Protocols. New York, NY: New York City Department of Health, 1994.
32. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. WHO/CDS/TB/2003.13. Geneva, Switzerland: WHO, 2003.
33. Li J, Burzynski J N, Lee Y A, et al. Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. Chest 2004; 126: 1770-1776.
34. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-1384.
35. Palella F J Jr, Delaney K M, Moorman A C, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.